Molina Healthcare Inc. (MOH) released its first‑quarter 2026 earnings on April 22, 2026, after the market close. The company reported revenue of $10.9 billion, a modest decline from the $10.95 billion consensus estimate, and an adjusted earnings per share (EPS) that fell short of the $1.68 consensus estimate. The miss reflects the company’s ongoing margin compression in its Medicaid business, which has been the primary driver of earnings pressure this year.
Revenue slipped 0.5% from the prior quarter and 1.2% from the same period a year earlier, largely because Medicaid premium growth slowed and specialty pharmacy costs rose. The company’s medical cost ratio (MCR) climbed to 94.6% in Q4 2025, a sharp increase from 90.2% a year earlier, underscoring the cost‑inflation pressure that has eroded profitability. The EPS miss was driven by the same factors: higher medical costs, increased behavioral‑health utilization, and higher home‑health service expenses, all of which have pushed the MCR above the 90% threshold that the company has historically targeted.
Comparing to prior periods, Molina’s Q1 2025 adjusted EPS was $6.08, while Q4 2025 reported an adjusted loss of $2.75 per share. The current quarter’s results therefore represent a significant decline in earnings quality, reflecting the company’s transition from a high‑margin period to a trough year for Medicaid margins. The decline also highlights the challenges the company faces in maintaining scale while managing rising costs.
Management guided for a full‑year 2026 adjusted EPS of at least $5.00, a figure that signals a cautious outlook. The guidance reflects the company’s view that 2026 will be a trough year for Medicaid margins, but it also indicates confidence that the company can stabilize earnings once cost‑control measures take effect and rate restorations begin to materialize. The guidance is unchanged from the prior guidance, underscoring management’s measured stance amid ongoing headwinds.
Segment‑level analysis shows that Medicaid revenue remained flat, while Medicare Advantage revenue grew modestly due to a 5.06% average rate increase for 2026. The company’s marketplace segment saw a slight decline, reflecting broader industry softness in that channel. The mix shift toward lower‑margin Medicaid contracts has been a key driver of the overall margin compression observed in the quarter.
Molina’s management emphasized that the company is focused on controlling medical costs and improving operational efficiency. They highlighted ongoing initiatives to streamline specialty pharmacy operations and to negotiate better rates with home‑health providers. These efforts are intended to reduce the MCR and restore profitability over the next few quarters.
In summary, Molina Healthcare’s Q1 2026 earnings underscored the company’s struggle to navigate a challenging Medicaid environment. While revenue remained near estimates, the EPS miss and margin compression signal that the company’s recovery plan will need to deliver tangible cost savings before earnings can rebound. The guidance points to a cautious outlook, with management expecting a gradual improvement as rate restorations and cost‑control measures take effect.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.